Indeed, crizotinib plus CDDP sensitized tumors to immunotherapy with antibodies blocking CTLA-4 and PD-1 (or PD-1 alone), allowing to induce a durable immune response, as well as complete cure against the majority of established orthotopic NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.